Dual functions of miR-200b in triple-negative breast cancer metastasis and chemoimmunoresistance

被引：1
|
作者：
Tan, Xiaohui [1 ]
Ren, Shuchang [1 ]
Lee, Woojin [1 ]
Wu, Xiaoling [2 ]
Rezaei, Katayoon [1 ]
Man, Yan-gao [3 ]
Latham, Patricia [1 ]
Siegel, Robert S. [1 ]
Brem, Rachel F. [1 ]
Li, Zhongwu [4 ]
Chang, Xiaofeng [5 ]
Fu, Sidney W. [1 ]
机构：
[1] George Washington Univ, Washington, DC USA
[2] Chengdu Mil Gen Hosp, Chengdu, Sichuan, Peoples R China
[3] Henry Jackson Fdn, Bethesda, MD USA
[4] Peking Univ, Hlth Sci Ctr, Beijing, Peoples R China
[5] Xi An Jiao Tong Univ, Coll Stomatol, Xian, Shaanxi, Peoples R China
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-498
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
498
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Syntelin inhibits triple-negative breast cancer cell proliferation and metastasis
    Mullen, McKay
    Yang, Fengrui
    Cao, Jun
    Cao, Yang
    Liu, Xu
    Lee, Gee Young
    Li, Tao
    Yao, William
    Yang, Zhihong
    Zhang, Jiahai
    Johnson, Kela
    Aikhionbare, Felix
    Chen, Yong
    Gao, Xinjiao
    Wang, Dongmei
    Ding, Xia
    Green, Hadiyah-Nicole
    Liu, Xing
    Yao, Xuebiao
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2021, 13 (11) : 834 - 837
  • [42] PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis
    A Paul
    S Gunewardena
    S R Stecklein
    B Saha
    N Parelkar
    M Danley
    G Rajendran
    P Home
    S Ray
    I Jokar
    G A Vielhauer
    R A Jensen
    O Tawfik
    S Paul
    Cell Death & Differentiation, 2014, 21 : 1469 - 1481
  • [43] Developing novel treatment strategies for triple-negative breast cancer metastasis
    Landis, Melissa D.
    Burey, Lacey A.
    Chang, Jenny C.
    CANCER RESEARCH, 2013, 73
  • [44] Diagnostic and Prognostic Nomograms for Lung Metastasis in Triple-Negative Breast Cancer
    Wang, Jianguo
    Zhao, Hongjun
    Ye, Lifen
    Li, Jingyong
    Zhang, Huaixiao
    Zhang, Chao
    Rao, Qishuo
    Cai, Yurong
    Xu, Yiping
    Deng, Youyuan
    COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2022, 2022
  • [45] PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis
    Paul, A.
    Gunewardena, S.
    Stecklein, S. R.
    Saha, B.
    Parelkar, N.
    Danley, M.
    Rajendran, G.
    Home, P.
    Ray, S.
    Jokar, I.
    Vielhauer, G. A.
    Jensen, R. A.
    Tawfik, O.
    Paul, S.
    CELL DEATH AND DIFFERENTIATION, 2014, 21 (09): : 1469 - 1481
  • [46] New insights into the discovery of drugs for triple-negative breast cancer metastasis
    Altei, Wanessa Fernanda
    Pachane, Bianca Cruz
    Souza, Cristiano
    Marques, Marcia Maria Chiquitelli
    Selistre-de-Araujo, Heloisa
    EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (04) : 365 - 376
  • [47] FGF13 promotes metastasis of triple-negative breast cancer
    Johnstone, Cameron N.
    Pattison, Andrew D.
    Harrison, Paul F.
    Powell, David R.
    Lock, Peter
    Ernst, Matthias
    Anderson, Robin L.
    Beilharz, Traude H.
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (01) : 230 - 243
  • [48] Repurposing mebendazole against triple-negative breast cancer CNS metastasis
    Adrian J. Rodrigues
    Sophia B. Chernikova
    Yuelong Wang
    Thy T. H. Trinh
    David E. Solow-Cordero
    Ludmila Alexandrova
    Kerriann M. Casey
    Elizabeth Alli
    Abhishek Aggarwal
    Tyler Quill
    Ashley K. Koegel
    Brian J. Feldman
    James M. Ford
    Melanie Hayden-Gephart
    Journal of Neuro-Oncology, 2024, 168 : 125 - 138
  • [49] Dual antisense oligonucleotide targeting miR-21/miR-155 synergize photodynamic therapy to treat triple-negative breast cancer and inhibit metastasis
    Shang, Mengdi
    Wu, Yiyang
    Wang, Yeyang
    Cai, Yanfei
    Jin, Jian
    Yang, Zhaoqi
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 146
  • [50] Isoliquiritigenin Suppresses EMT-Induced Metastasis in Triple-Negative Breast Cancer through miR-200c/C-JUN/β-Catenin
    Peng, Fu
    Tang, Hailin
    Du, Junrong
    Chen, Jianping
    Peng, Cheng
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2021, 49 (02): : 505 - 523
12345